Champions Oncology Files 8-K on Security Holder Votes
Ticker: CSBR · Form: 8-K · Filed: Oct 16, 2025 · CIK: 771856
| Field | Detail |
|---|---|
| Company | Champions Oncology, INC. (CSBR) |
| Form Type | 8-K |
| Filed Date | Oct 16, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
Champions Oncology shareholders voted on something important October 16th.
AI Summary
Champions Oncology, Inc. filed an 8-K on October 16, 2025, to report on matters submitted to a vote of its security holders. The filing does not contain specific details about the voting matters or any financial transactions.
Why It Matters
This filing indicates that Champions Oncology held a vote of its shareholders, which could pertain to significant corporate decisions or governance changes.
Risk Assessment
Risk Level: low — The filing is a routine procedural report and does not disclose any new financial information or significant business changes.
Key Players & Entities
- CHAMPIONS ONCOLOGY, INC. (company) — Registrant
- October 16, 2025 (date) — Date of report
FAQ
What specific matters were submitted to a vote of Champions Oncology's security holders on October 16, 2025?
The filing does not specify the exact matters submitted for a vote, only that such matters were presented.
Were there any significant outcomes or results from the security holder vote reported in this 8-K?
This 8-K filing reports the submission of matters to a vote, but does not detail the outcomes or results of that vote.
Does this filing disclose any financial transactions or new business developments for Champions Oncology?
No, this 8-K filing is specifically for reporting the submission of matters to a vote of security holders and does not disclose financial transactions or new business developments.
What is the principal executive office address for Champions Oncology, Inc. as listed in the filing?
The address of the Principal Executive Office is listed as 1 University Plaza, Suite 307, Hackensack, New Jersey 07601.
What is the SIC code for Champions Oncology, Inc.?
The Standard Industrial Classification (SIC) code for Champions Oncology, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 605 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2025-10-16 17:05:37
Key Financial Figures
- $0.001 — ich Registered Common Stock, par value $0.001 per share CSBR The Nasdaq Stock Market
Filing Documents
- csbr-20251016.htm (8-K) — 47KB
- 0001628280-25-045241.txt ( ) — 173KB
- csbr-20251016.xsd (EX-101.SCH) — 2KB
- csbr-20251016_def.xml (EX-101.DEF) — 4KB
- csbr-20251016_lab.xml (EX-101.LAB) — 23KB
- csbr-20251016_pre.xml (EX-101.PRE) — 14KB
- csbr-20251016_htm.xml (XML) — 3KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. On October 16, 2025, Champions Oncology, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting"). The following matters were submitted to a vote of the stockholders at the Annual Meeting and the voting results were as follows: 1. Election of Directors. The seven director nominees named in the Company's 2025 proxy statement were elected to serve for a one-year term expiring at the 2026 Annual Meeting of Stockholders or until their successors are duly elected and qualified, based upon the following votes: Director Nominee Votes For Votes Withheld Broker Non-Vote Ronnie Morris, M.D. 8,992,111 735,954 931,779 Joel Ackerman 8,991,092 736,973 931,779 Robert Brainin 8,894,744 833,321 931,779 David Sidransky, M.D. 8,703,235 1,024,830 931,779 Daniel Mendelson 9,240,584 487,481 931,779 Scott R. Tobin 9,722,734 5,331 931,779 Philip Breitfeld, MD. 9,722,113 5,952 931,779 2. Ratification of Appointment of Independent Registered Accounting Firm. The appointment of EisnerAmper LLP to serve as the Company's independent registered public accounting firm for the fiscal year ending April 30, 2026, was ratified as follows: Votes For Votes Against Abstain 10,659,115 729 — 3. Non-binding Advisory Resolution Relating to the Compensation of the Company's Named Executive Officers. The proposal to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, as described in the Company's 2025 proxy statement, was approved by the following votes: Votes For Votes Against Abstain Broker Non-Vote 9,720,681 7,262 122 931,779
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CHAMPIONS ONCOLOGY, INC. (Registrant) Date: October 16, 2025 By: /s/ David Miller David Miller Chief Financial Officer